Is Harmony Biosciences Stock a Good Investment?
Harmony Biosciences Investment Advice | HRMY |
- Examine Harmony Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Harmony Biosciences' leadership team and their track record. Good management can help Harmony Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Harmony Biosciences' business and its evolving consumer preferences.
- Compare Harmony Biosciences' performance and market position to its competitors. Analyze how Harmony Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Harmony Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Harmony Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Harmony Biosciences Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Harmony Biosciences Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Harmony Biosciences Stock
Researching Harmony Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 20.0% of the company shares are held by company insiders. The book value of Harmony Biosciences was currently reported as 9.48. The company has Price/Earnings (P/E) ratio of 293.37. Harmony Biosciences had not issued any dividends in recent years.
To determine if Harmony Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Harmony Biosciences' research are outlined below:
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from accesswire.com: Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi Korsinsky Regarding Potential Securities Law Violations - HRMY |
Harmony Biosciences Quarterly Accounts Payable |
|
Harmony Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Harmony Biosciences Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Harmony Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Harmony Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Harmony Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-02 | 2022-06-30 | 0.44 | 0.39 | -0.05 | 11 | ||
2021-08-10 | 2021-06-30 | 0.18 | 0.24 | 0.06 | 33 | ||
2024-04-30 | 2024-03-31 | 0.6 | 0.67 | 0.07 | 11 | ||
2023-08-01 | 2023-06-30 | 0.63 | 0.56 | -0.07 | 11 | ||
2020-11-12 | 2020-09-30 | -0.05 | -0.14 | -0.09 | 180 | ||
2023-10-31 | 2023-09-30 | 0.65 | 0.75 | 0.1 | 15 | ||
2021-03-25 | 2020-12-31 | 0.09 | 0.25 | 0.16 | 177 | ||
2023-05-02 | 2023-03-31 | 0.47 | 0.66 | 0.19 | 40 |
Know Harmony Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Harmony Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Harmony Biosciences Holdings backward and forwards among themselves. Harmony Biosciences' institutional investor refers to the entity that pools money to purchase Harmony Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-06-30 | 684.3 K | American Century Companies Inc | 2024-06-30 | 681.5 K | Renaissance Technologies Corp | 2024-06-30 | 595.8 K | Lsv Asset Management | 2024-06-30 | 578.2 K | Federated Hermes Inc | 2024-06-30 | 525.5 K | Massachusetts Financial Services Company | 2024-06-30 | 519.7 K | Goldman Sachs Group Inc | 2024-06-30 | 455.4 K | Charles Schwab Investment Management Inc | 2024-06-30 | 374.7 K | Voloridge Investment Management, Llc | 2024-06-30 | 335.4 K | Valor Management Llc | 2024-06-30 | 11.2 M | Blackrock Inc | 2024-06-30 | 5.8 M |
Harmony Biosciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.98 B.Market Cap |
|
Harmony Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.19 | 0.20 | |
| Return On Capital Employed | 0.30 | 0.31 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 0.28 | 0.26 |
Determining Harmony Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Harmony Biosciences is a good buy. For example, gross profit margin measures Harmony Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Harmony Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Harmony Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Harmony Biosciences Holdings. Check Harmony Biosciences' Beneish M Score to see the likelihood of Harmony Biosciences' management manipulating its earnings.
Evaluate Harmony Biosciences' management efficiency
Harmony Biosciences has return on total asset (ROA) of 0.1375 % which means that it generated a profit of $0.1375 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2247 %, meaning that it created $0.2247 on every $100 dollars invested by stockholders. Harmony Biosciences' management efficiency ratios could be used to measure how well Harmony Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Harmony Biosciences' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.31 in 2024, whereas Return On Equity is likely to drop 0.26 in 2024. At this time, Harmony Biosciences' Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 105.3 M in 2024, whereas Total Assets are likely to drop slightly above 466 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.85 | 8.25 | |
| Tangible Book Value Per Share | 5.55 | 5.82 | |
| Enterprise Value Over EBITDA | 7.79 | 7.41 | |
| Price Book Value Ratio | 4.11 | 4.32 | |
| Enterprise Value Multiple | 7.79 | 7.41 | |
| Price Fair Value | 4.11 | 4.32 | |
| Enterprise Value | 1.8 B | 1.9 B |
The analysis of Harmony Biosciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Harmony Biosciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Harmony Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.734 |
Basic technical analysis of Harmony Stock
As of the 11th of October 2024, Harmony Biosciences retains the Downside Deviation of 2.5, market risk adjusted performance of 0.0703, and Risk Adjusted Performance of 0.0355. Harmony Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Harmony Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Harmony Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Harmony Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Harmony Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Harmony Biosciences' Outstanding Corporate Bonds
Harmony Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Harmony Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Harmony bonds can be classified according to their maturity, which is the date when Harmony Biosciences Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Harmony Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Harmony Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0355 | |||
| Market Risk Adjusted Performance | 0.0703 | |||
| Mean Deviation | 1.91 | |||
| Semi Deviation | 2.41 | |||
| Downside Deviation | 2.5 | |||
| Coefficient Of Variation | 2865.67 | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.73 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0603 | |||
| Maximum Drawdown | 16.06 | |||
| Value At Risk | (3.37) | |||
| Potential Upside | 4.4 | |||
| Downside Variance | 6.26 | |||
| Semi Variance | 5.81 | |||
| Expected Short fall | (2.12) | |||
| Skewness | (0.24) | |||
| Kurtosis | 2.28 |
| Risk Adjusted Performance | 0.0355 | |||
| Market Risk Adjusted Performance | 0.0703 | |||
| Mean Deviation | 1.91 | |||
| Semi Deviation | 2.41 | |||
| Downside Deviation | 2.5 | |||
| Coefficient Of Variation | 2865.67 | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.73 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0603 | |||
| Maximum Drawdown | 16.06 | |||
| Value At Risk | (3.37) | |||
| Potential Upside | 4.4 | |||
| Downside Variance | 6.26 | |||
| Semi Variance | 5.81 | |||
| Expected Short fall | (2.12) | |||
| Skewness | (0.24) | |||
| Kurtosis | 2.28 |
Consider Harmony Biosciences' intraday indicators
Harmony Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Harmony Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Harmony Biosciences Corporate Filings
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 1st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 6th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 11th of April 2024 Other Reports | ViewVerify |
Harmony Stock media impact
Far too much social signal, news, headlines, and media speculation about Harmony Biosciences that are available to investors today. That information is available publicly through Harmony media outlets and privately through word of mouth or via Harmony internal channels. However, regardless of the origin, that massive amount of Harmony data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Harmony Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Harmony Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Harmony Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Harmony Biosciences alpha.
Harmony Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Harmony Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Harmony Biosciences Historical Investor Sentiment
Investor biases related to Harmony Biosciences' public news can be used to forecast risks associated with an investment in Harmony. The trend in average sentiment can be used to explain how an investor holding Harmony can time the market purely based on public headlines and social activities around Harmony Biosciences Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Harmony Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Harmony Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Harmony Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Harmony Biosciences.
Harmony Biosciences Corporate Management
| Brennan Doyle | VP Relations | Profile | |
| Audrey Murphy | Head Resources | Profile | |
| David Bradshaw | Head Operations | Profile | |
| Cate McCanless | Head Policy | Profile | |
| MBA JD | Executive Officer | Profile | |
| Audrey SPHR | Head Resources | Profile | |
| Jeffrey Aronin | Founder Chairman | Profile |
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.